Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

NCT04109482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons.

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions

BIOLOGICAL: MB-102
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Mustang Bio